150 related articles for article (PubMed ID: 8913841)
1. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Forsyth P; Cairncross G; Stewart D; Goodyear M; Wainman N; Eisenhauer E
Invest New Drugs; 1996; 14(2):203-6. PubMed ID: 8913841
[TBL] [Abstract][Full Text] [Related]
2. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study.
Sanson M; Napolitano M; Yaya R; Keime-Guibert F; Broët P; Hoang-Xuan K; Delattre JY
J Neurooncol; 2000 Dec; 50(3):245-9. PubMed ID: 11263504
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Dreyfuss AI; Clark JR; Norris CM; Rossi RM; Lucarini JW; Busse PM; Poulin MD; Thornhill L; Costello R; Posner MR
J Clin Oncol; 1996 May; 14(5):1672-8. PubMed ID: 8622087
[TBL] [Abstract][Full Text] [Related]
4. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
Fossella FV; Lee JS; Murphy WK; Lippman SM; Calayag M; Pang A; Chasen M; Shin DM; Glisson B; Benner S
J Clin Oncol; 1994 Jun; 12(6):1238-44. PubMed ID: 7911160
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
Fossella FV; Lee JS; Shin DM; Calayag M; Huber M; Perez-Soler R; Murphy WK; Lippman S; Benner S; Glisson B
J Clin Oncol; 1995 Mar; 13(3):645-51. PubMed ID: 7884425
[TBL] [Abstract][Full Text] [Related]
7. Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.
Shapiro JD; Millward MJ; Rischin D; Davison JD; Michael M; Francis PA; Ganju V; Toner GC
Aust N Z J Med; 1997 Feb; 27(1):40-4. PubMed ID: 9079252
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of paclitaxel in patients with recurrent malignant glioma.
Prados MD; Schold SC; Spence AM; Berger MS; McAllister LD; Mehta MP; Gilbert MR; Fulton D; Kuhn J; Lamborn K; Rector DJ; Chang SM
J Clin Oncol; 1996 Aug; 14(8):2316-21. PubMed ID: 8708723
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy.
Einzig AI; Schuchter LM; Recio A; Coatsworth S; Rodriquez R; Wiernik PH
Med Oncol; 1996 Jun; 13(2):111-7. PubMed ID: 9013474
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Mertens WC; Eisenhauer EA; Jolivet J; Ernst S; Moore M; Muldal A
Ann Oncol; 1994 Feb; 5(2):185-7. PubMed ID: 7910480
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.
Einzig AI; Neuberg D; Remick SC; Karp DD; O'Dwyer PJ; Stewart JA; Benson AB
Med Oncol; 1996 Jun; 13(2):87-93. PubMed ID: 9013471
[TBL] [Abstract][Full Text] [Related]
12. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
Adachi I; Watanabe T; Takashima S; Narabayashi M; Horikoshi N; Aoyama H; Taguchi T
Br J Cancer; 1996 Jan; 73(2):210-6. PubMed ID: 8546908
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R
J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
[TBL] [Abstract][Full Text] [Related]
15. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
16. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Ravdin PM; Valero V
Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
Bedikian AY; Weiss GR; Legha SS; Burris HA; Eckardt JR; Jenkins J; Eton O; Buzaid AC; Smetzer L; Von Hoff DD
J Clin Oncol; 1995 Dec; 13(12):2895-9. PubMed ID: 8523052
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Picus J; Schultz M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B; Fumoleau P; Kerbrat P; Dieras V; Roche H; Krakowski I; Azli N; Bayssas M; Lentz MA; Van Glabbeke M
J Clin Oncol; 1995 Feb; 13(2):314-22. PubMed ID: 7844592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]